- HPV vaccine coverage among French men who have sex with men (MSM) is low and associated with infrequent physician-driven uptake.
Why this matters
- Discuss, offer HPV vaccine uptake in MSM, especially those under age 27 years.
- Address vaccine hesitancy using data demonstrating direct link between vaccination and cancer prevention/reduction.
- 2094 MSM; mean age, 35.4±11 years (24.3% represented HPV vaccine targeted age class).
- Overall, using a 1-10 scale, participants scored items as follows:
- Vaccination: 10 (interquartile range [IQR], 8-10);
- Vaccine usefulness: 10 (IQR, 9-10; Rho=0.848; P<.001>
- Vaccine harmfulness: 2 (IQR, 2-5).
- Positive correlation seen for vaccine usefulness in favor of vaccination (Rho=0.848; P<.001>
- MSM taking preexposure prophylaxis (PrEP) had higher perception of vaccine utility (P<.001>
- 16.5% (345) of participants with ≥1 physician vs 9.9% (171, 9.9% in target age class) with a family physician had HPV vaccination offered to them.
- 17.9% (90/541) of participants in target age class received ≥1 vaccine dose; 52.2% (21/40) were using PrEP.
- 45.7% (839) would accept HPV vaccination if offered.
- Online survey to determine HPV vaccine coverage among French MSM, including physician recommendations, vaccine perceptions, October 2018-January 2019.
- Funding: None disclosed.
- Limited generalizability.
- Self-report bias.